Annual CFO
-$20.94 M
-$181.00 K-0.87%
December 31, 2023
Summary
- As of February 7, 2025, ATOS annual cash flow from operations is -$20.94 million, with the most recent change of -$181.00 thousand (-0.87%) on December 31, 2023.
- During the last 3 years, ATOS annual CFO has fallen by -$9.37 million (-80.99%).
- ATOS annual CFO is now -5747.81% below its all-time high of -$358.10 thousand, reached on December 31, 2010.
Performance
ATOS Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFO
-$4.75 M
-$219.00 K-4.83%
September 30, 2024
Summary
- As of February 7, 2025, ATOS quarterly cash flow from operations is -$4.75 million, with the most recent change of -$219.00 thousand (-4.83%) on September 30, 2024.
- Over the past year, ATOS quarterly CFO has dropped by -$867.00 thousand (-22.33%).
- ATOS quarterly CFO is now -847.44% below its all-time high of $635.50 thousand, reached on September 30, 2016.
Performance
ATOS Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFO
-$19.55 M
-$867.00 K-4.64%
September 30, 2024
Summary
- As of February 7, 2025, ATOS TTM cash flow from operations is -$19.55 million, with the most recent change of -$867.00 thousand (-4.64%) on September 30, 2024.
- Over the past year, ATOS TTM CFO has increased by +$343.00 thousand (+1.72%).
- ATOS TTM CFO is now -291691.04% below its all-time high of -$6700.00, reached on March 31, 2011.
Performance
ATOS TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
ATOS Cash From Operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -0.9% | -22.3% | +1.7% |
| 3 y3 years | -81.0% | -55.1% | -20.4% |
| 5 y5 years | -133.7% | -55.1% | -20.4% |
ATOS Cash From Operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -27.1% | at low | -29.6% | +32.4% | -18.7% | +14.6% |
| 5 y | 5-year | -129.4% | at low | -113.1% | +32.4% | -114.2% | +14.6% |
| alltime | all time | -5747.8% | at low | -847.4% | +32.4% | <-9999.0% | +14.6% |
Atossa Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$4.75 M(+4.8%) | -$19.55 M(+4.6%) |
| Jun 2024 | - | -$4.53 M(-3.6%) | -$18.68 M(+0.4%) |
| Mar 2024 | - | -$4.70 M(-15.7%) | -$18.62 M(-11.1%) |
| Dec 2023 | -$20.94 M(+0.9%) | -$5.57 M(+43.5%) | -$20.94 M(+5.3%) |
| Sep 2023 | - | -$3.88 M(-13.0%) | -$19.89 M(-7.1%) |
| Jun 2023 | - | -$4.46 M(-36.4%) | -$21.42 M(-6.5%) |
| Mar 2023 | - | -$7.02 M(+55.3%) | -$22.90 M(+10.3%) |
| Dec 2022 | -$20.76 M(+26.0%) | -$4.52 M(-16.4%) | -$20.76 M(+4.3%) |
| Sep 2022 | - | -$5.41 M(-9.1%) | -$19.90 M(+13.4%) |
| Jun 2022 | - | -$5.95 M(+22.0%) | -$17.55 M(+3.6%) |
| Mar 2022 | - | -$4.88 M(+33.1%) | -$16.94 M(+2.9%) |
| Dec 2021 | -$16.47 M(+42.4%) | -$3.67 M(+19.7%) | -$16.47 M(+1.4%) |
| Sep 2021 | - | -$3.06 M(-42.6%) | -$16.24 M(+2.4%) |
| Jun 2021 | - | -$5.34 M(+21.1%) | -$15.86 M(+24.4%) |
| Mar 2021 | - | -$4.41 M(+28.4%) | -$12.75 M(+10.2%) |
| Dec 2020 | -$11.57 M(+26.7%) | -$3.43 M(+28.2%) | -$11.57 M(+6.7%) |
| Sep 2020 | - | -$2.68 M(+20.1%) | -$10.85 M(+9.2%) |
| Jun 2020 | - | -$2.23 M(-31.0%) | -$9.94 M(-2.7%) |
| Mar 2020 | - | -$3.23 M(+19.3%) | -$10.21 M(+11.8%) |
| Dec 2019 | -$9.13 M(+1.9%) | -$2.71 M(+53.1%) | -$9.13 M(+3.0%) |
| Sep 2019 | - | -$1.77 M(-29.3%) | -$8.86 M(-5.6%) |
| Jun 2019 | - | -$2.50 M(+16.4%) | -$9.39 M(+7.7%) |
| Mar 2019 | - | -$2.15 M(-12.1%) | -$8.72 M(-2.7%) |
| Dec 2018 | -$8.96 M(+35.9%) | -$2.44 M(+6.3%) | -$8.96 M(+9.3%) |
| Sep 2018 | - | -$2.30 M(+25.4%) | -$8.20 M(+7.8%) |
| Jun 2018 | - | -$1.83 M(-23.2%) | -$7.60 M(+6.8%) |
| Mar 2018 | - | -$2.39 M(+41.8%) | -$7.12 M(+8.0%) |
| Dec 2017 | -$6.59 M | -$1.68 M(-1.1%) | -$6.59 M(+5.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2017 | - | -$1.70 M(+26.2%) | -$6.27 M(+59.5%) |
| Jun 2017 | - | -$1.35 M(-27.5%) | -$3.93 M(-7.3%) |
| Mar 2017 | - | -$1.86 M(+37.2%) | -$4.24 M(-21.1%) |
| Dec 2016 | -$5.37 M(-61.5%) | -$1.36 M(-313.4%) | -$5.37 M(-32.6%) |
| Sep 2016 | - | $635.50 K(-138.3%) | -$7.97 M(-34.1%) |
| Jun 2016 | - | -$1.66 M(-44.6%) | -$12.09 M(-13.3%) |
| Mar 2016 | - | -$2.99 M(-24.2%) | -$13.95 M(-0.0%) |
| Dec 2015 | -$13.95 M(+32.2%) | -$3.95 M(+13.6%) | -$13.95 M(+9.7%) |
| Sep 2015 | - | -$3.48 M(-1.1%) | -$12.72 M(+4.1%) |
| Jun 2015 | - | -$3.52 M(+17.4%) | -$12.22 M(+11.6%) |
| Mar 2015 | - | -$3.00 M(+10.3%) | -$10.95 M(+3.7%) |
| Dec 2014 | -$10.56 M(+19.5%) | -$2.72 M(-8.7%) | -$10.56 M(+0.7%) |
| Sep 2014 | - | -$2.98 M(+32.1%) | -$10.48 M(+2.3%) |
| Jun 2014 | - | -$2.25 M(-13.4%) | -$10.24 M(+1.4%) |
| Mar 2014 | - | -$2.60 M(-1.7%) | -$10.10 M(+14.4%) |
| Dec 2013 | -$8.83 M(+126.4%) | -$2.65 M(-3.3%) | -$8.83 M(+8.8%) |
| Sep 2013 | - | -$2.74 M(+29.8%) | -$8.11 M(+46.8%) |
| Jun 2013 | - | -$2.11 M(+58.0%) | -$5.53 M(+30.7%) |
| Mar 2013 | - | -$1.33 M(-30.9%) | -$4.23 M(+8.5%) |
| Dec 2012 | -$3.90 M(+11.7%) | -$1.93 M(+1179.7%) | -$3.90 M(+29.7%) |
| Sep 2012 | - | -$151.00 K(-81.4%) | -$3.01 M(-28.4%) |
| Jun 2012 | - | -$811.50 K(-19.3%) | -$4.20 M(-6.5%) |
| Mar 2012 | - | -$1.01 M(-3.2%) | -$4.49 M(+28.6%) |
| Dec 2011 | -$3.49 M(+875.3%) | -$1.04 M(-22.7%) | -$3.49 M(+42.3%) |
| Sep 2011 | - | -$1.34 M(+21.9%) | -$2.45 M(+121.2%) |
| Jun 2011 | - | -$1.10 M(>+9900.0%) | -$1.11 M(>+9900.0%) |
| Mar 2011 | - | -$6700.00 | -$6700.00 |
| Dec 2010 | -$358.10 K | - | - |
FAQ
- What is Atossa Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for Atossa Therapeutics?
- What is Atossa Therapeutics annual CFO year-on-year change?
- What is Atossa Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for Atossa Therapeutics?
- What is Atossa Therapeutics quarterly CFO year-on-year change?
- What is Atossa Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for Atossa Therapeutics?
- What is Atossa Therapeutics TTM CFO year-on-year change?
What is Atossa Therapeutics annual cash flow from operations?
The current annual CFO of ATOS is -$20.94 M
What is the all time high annual CFO for Atossa Therapeutics?
Atossa Therapeutics all-time high annual cash flow from operations is -$358.10 K
What is Atossa Therapeutics annual CFO year-on-year change?
Over the past year, ATOS annual cash flow from operations has changed by -$181.00 K (-0.87%)
What is Atossa Therapeutics quarterly cash flow from operations?
The current quarterly CFO of ATOS is -$4.75 M
What is the all time high quarterly CFO for Atossa Therapeutics?
Atossa Therapeutics all-time high quarterly cash flow from operations is $635.50 K
What is Atossa Therapeutics quarterly CFO year-on-year change?
Over the past year, ATOS quarterly cash flow from operations has changed by -$867.00 K (-22.33%)
What is Atossa Therapeutics TTM cash flow from operations?
The current TTM CFO of ATOS is -$19.55 M
What is the all time high TTM CFO for Atossa Therapeutics?
Atossa Therapeutics all-time high TTM cash flow from operations is -$6700.00
What is Atossa Therapeutics TTM CFO year-on-year change?
Over the past year, ATOS TTM cash flow from operations has changed by +$343.00 K (+1.72%)